Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cholinergic Integrity in Down Syndrome
NCT05231798Phase 2Recruiting
- Sponsor
- Vanderbilt University Medical Center
- Start
- Aug 2021
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluoroethoxybenzovesamicol in Down syndrome, sponsored by Vanderbilt University Medical Center. Primary endpoint: [18F]-FEOBV radiotracer standardized uptake value ratio correlation with the Basal Forebrain Cholinergic System Volume at 3 years. Started Aug 2021; status: recruiting.
02
Drugs
fluoroethoxybenzovesamicol
03
Conditions
Down syndrome
Beyond the preview
Go deeper on NCT05231798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05231798.